Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Cash from Investing Activities data on file, last reported at -$325000.0 in Q1 2026.

• Quarterly Cash from Investing Activities fell 2400.0% year-over-year to -$325000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 104.11% YoY) and the FY2025 annual result came in at -$696000.0, down 114.25% from the prior year.
• Cash from Investing Activities climbed to -$325000.0 in Q1 2026, from -$333000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $14.9 million in Q4 2023 to a low of -$44.0 million in Q1 2023.
• A 5-year average of $1.9 million and a median of $6.7 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 118.44% — and 2026, when it tumbled 2400.0%.
• Tracing XERS's Cash from Investing Activities over 5 years: stood at $9.2 million in 2022, then soared by 62.17% to $14.9 million in 2023, then plunged by 32.63% to $10.0 million in 2024, then tumbled by 103.32% to -$333000.0 in 2025, then climbed by 2.4% to -$325000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$325000.0 (Q1 2026), -$333000.0 (Q4 2025), and -$71000.0 (Q3 2025), per Business Quant data.